实时影像引导糖尿病视网膜病变管理:PRIME随机试验结果
PRIME试验将40只无糖尿病黄斑水肿的DR眼随机分为DRSS引导组和PLI引导组,评估按需阿柏西普注射的安全性及疗效。52周时95%眼达到DRSS改善≥2级,但需PRN注射者中DRSS引导组100%恶化而PLI引导组59%恶化,PLI恶化似先于DRSS恶化。
要点
- 95%无DME的DR眼经每月IAI后达到DRSS改善≥2级。
- 需PRN注射者中,DRSS引导组100%恶化,PLI引导组59%恶化(P=.01)。
- PLI引导组平均PLI下降54.6%(P<.0001),DRSS引导组下降18.2%(P=.49)。
核心结论
- 在无DME的DR眼中,PLI恶化似乎先于DRSS水平恶化,多数患者需每3-4个月重复IAI治疗。
研究设计与样本
- 前瞻性随机2期试验(PRIME),40只NPDR或PDR眼接受每月IAI至DRSS改善≥2级后,1:1随机至DRSS引导或PLI引导管理组,由中心阅片中心分级。
主要发现
- 至52周,95%眼达到DRSS改善≥2级;DRSS改善后97%眼需至少1次PRN IAI。
- 需PRN IAI且完成52周的眼,DRSS引导组100%和PLI引导组59%出现DRSS恶化(P=.01)。
- 至52周,DRSS引导组平均PLI下降18.2%(P=.49),PLI引导组下降54.6%(P<.0001)。
- 基线NPDR眼平均4.9次IAI后达到DRSS改善≥2级,PDR眼平均3.6次(P=.03)。
- 2只眼在病变静止5个月后于52周发生PDR事件。
关键数值与推荐
- DRSS改善≥2级定义为治疗目标;PRN管理分别以实时DRSS水平或PLI评估为引导。
临床怎么用
- 对无DME的DR眼,可在DRSS改善后采用PLI引导的PRN策略,并需密切临床随访。
局限性
- 研究样本量小(40眼),为2期试验,结论受研究背景限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the safety and efficacy of as-needed (PRN) intravitreal aflibercept injections (IAI) in managing diabetic retinopathy (DR) guided by the real-time DR severity scale (DRSS) level or panretinal leakage index (PLI) assessment among eyes without diabetic macular edema (DME). DESIGN: Prospective, randomized phase 2 trial (PRIME). METHODS: A total of 40 eyes with nonproliferative (NPDR) or proliferative DR (PDR) received monthly IAIs until a DRSS improvement of ≥2 steps was achieved and eyes were randomized (1:1) to DRSS-guided or PLI-guided management strategies graded by a central reading center. Main outcome measurements included safety and changes in DRSS and PLI. RESULTS: Through week 52, 95% of eyes achieved a DRSS improvement of ≥2 steps. Following DRSS improvement, 97% of eyes required at least 1 PRN IAI. In eyes requiring PRN IAI and completing week 52, 100% and 59% experienced DRSS worsening (P = .01) in the DRSS- and PLI-guided arms, respectively. Through week 52, mean PLI decreased 18.2% (P = .49) and 54.6% (P <.0001), respectively, in the DRSS- and PLI-guided arms. NPDR versus PDR eyes at baseline achieved a DRSS improvement of ≥2 steps after a mean 4.9 and 3.6 IAIs (P = .03). Two eyes developed a PDR event at week 52 following 5 months of quiescence. CONCLUSIONS: The randomized PRIME study analyzed 2 imaging-based biomarkers to guide PRN management with IAI of DR without DME: DRSS level and PLI. Within the context of this study with limitations, most patients required IAI re-treatment every 3-4 months, and deterioration of PLI appeared to precede DRSS level worsening. Finally, these findings reaffirm the fact that close clinical follow-up is important even among eyes that achieve substantial DRSS improvements with apparently quiescent disease.
引用
- Yu HJ, Ehlers JP, Sevgi DD, et al. Real-Time Photographic- and Fluorescein Angiographic-Guided Management of Diabetic Retinopathy: Randomized PRIME Trial Outcomes. Am J Ophthalmol. 2021. PMID: 33529593. doi:10.1016/j.ajo.2021.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。